ABBV CLS 484
Alternative Names: ABBV-CLS-484Latest Information Update: 12 Jun 2024
At a glance
- Originator Calico
- Class Antineoplastics; Small molecules
- Mechanism of Action Protein tyrosine phosphatase non receptor type 1 antagonists; Protein tyrosine phosphatase non-receptor type 2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 12 Jun 2024 ABBV CLS 484 is still in phase I trials for Solid tumours in Spain, Japan, Israel, France and the US (AbbVie Pipeline, June 2024)
- 28 Apr 2024 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in France (PO, Capsule)
- 28 Apr 2024 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Israel (PO, Capsule)